Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Hybrid Surgical/Interventional LV Reconstruction Improves Ejection Fraction and Patient Symptoms

Michael O'Riordan

June 27, 2018

News Conference News The Structural Heart Disease Summit 2018

Trade-offs Between Self-Expanding and Balloon-Expandable Valves in Very Large Annuli

Michael O'Riordan

June 26, 2018

News Conference News The Structural Heart Disease Summit 2018

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Michael O'Riordan

June 23, 2018

News Conference News The Structural Heart Disease Summit 2018

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Michael O'Riordan

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Raj Makkar

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Raj Makkar, Maria Alu, MS

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Raj Makkar, Lars Sondergaard

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Surgical Perspectives of TMVR: Focus on Patient Selection and Clinical Management Issues

Presenter: Martin B. Leon, Gregg W. Stone, Michael J. Mack

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presenter: Susheel K. Kodali, Michael J. Reardon, Mathew Williams

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Perspectives From the STS/ACC TVT Registry: Factors That Impact Clinical Outcomes

Presenter: Michael J. Mack, John D. Carroll

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

New Standards for SAVR and TAVR Bioprosthetic Valve Dysfunction and Failure: A Consensus Statement from EAPCI, ESC, and EACTS

Presenter: Michael J. Mack, Bernard Prendergast

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

An Introduction to VARC-3: A Focused Update New Endpoints and Definitions for Aortic Valve Clinical Research

Presenter: Michael J. Mack, Nicolo Piazza

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Refining the Innovation Process in the US: Evolution to an Early Feasibility Study (EFS) Network

Presenter: Michael J. Mack

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Innovative FDA Approaches to Future Clinical Research: Proposal for a Cardiac Device Coordinated Research Network (CDCRN)

Presenter: Michael J. Mack, John C Laschinger

June 21, 2018

News Conference News The Structural Heart Disease Summit 2018

Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year

Michael O'Riordan

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

A Surgeons Perspective of Bicuspid Aortic Valve Disease Anatomic Patterns Favorable for TAVR

Presenter: John C Laschinger, Mathew Williams, Michael J. Mack

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Case #3: A Small (Undersized) Surgical Bioprosthesis

Presenter: Michael J. Reardon, Adnan K. Chhatriwalla, Danny Dvir, Ariel Finkelstein, Kendra J. Grubb, Michael J. Mack, Thomas Modine, Mark J. Russo

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Case #2: A Stentless (or Stented With Leaflets Outside the Stent) Surgical Bioprosthesis

Presenter: Brian K. Whisenant, Adnan K. Chhatriwalla, Danny Dvir, Ariel Finkelstein, Kendra J. Grubb, Michael J. Mack, Thomas Modine, Mark J. Russo

June 21, 2018

Advertisement

Hybrid Surgical/Interventional LV Reconstruction Improves Ejection Fraction and Patient Symptoms

Trade-offs Between Self-Expanding and Balloon-Expandable Valves in Very Large Annuli

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

High-Quality TAVR: Does a Minimum Volume Requirement Still Make Sense?

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Surgical Perspectives of TMVR: Focus on Patient Selection and Clinical Management Issues

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Perspectives From the STS/ACC TVT Registry: Factors That Impact Clinical Outcomes

New Standards for SAVR and TAVR Bioprosthetic Valve Dysfunction and Failure: A Consensus Statement from EAPCI, ESC, and EACTS

An Introduction to VARC-3: A Focused Update New Endpoints and Definitions for Aortic Valve Clinical Research

Refining the Innovation Process in the US: Evolution to an Early Feasibility Study (EFS) Network

Innovative FDA Approaches to Future Clinical Research: Proposal for a Cardiac Device Coordinated Research Network (CDCRN)

Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

A Surgeons Perspective of Bicuspid Aortic Valve Disease Anatomic Patterns Favorable for TAVR

Case #3: A Small (Undersized) Surgical Bioprosthesis

Case #2: A Stentless (or Stented With Leaflets Outside the Stent) Surgical Bioprosthesis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content